Author:
Wang Xue,Liu Ying,Xu Wanjia,Jia Lirui,Chi Dongxu,Yu Jiang,Wang Jiamei,He Zhonggui,Liu Xiaohong,Wang Yongjun
Funder
National Major Science and Technology Projects of China
Publisher
Springer Science and Business Media LLC
Reference29 articles.
1. Messerer CL, Ramsay EC, Waterhouse D, Ng R, Simms EM, Harasym N, et al. Liposomal irinotecan: formulation development and therapeutic assessment in murine xenograft models of colorectal cancer. Clin Cancer Res. 2004;10(19):6638–49. https://doi.org/10.1158/1078-0432.Ccr-04-0221.
2. Xenidis N, Vardakis N, Varthalitis I, Giassas S, Kontopodis E, Ziras N, et al. A multicenter phase II study of pegylated liposomal doxorubicin in combination with irinotecan as second-line treatment of patients with refractory small-cell lung cancer. Cancer Chemother Pharmacol. 2011;68(1):63–8. https://doi.org/10.1007/s00280-010-1427-5.
3. Bailly C. Irinotecan: 25 years of cancer treatment. Pharmacological research. 2019;148:104398-.
https://doi.org/10.1016/j.phrs.2019.104398.
4. Mallick P, Shah P, Ittmann MM, Trivedi M, Hu M, Gao S, et al. Impact of diet on irinotecan toxicity in mice. Chem Biol Interact. 2018;291:87–94. https://doi.org/10.1016/j.cbi.2018.06.018.
5. Mathijssen RH, van Alphen RJ, Verweij J, Loos WJ, Nooter K, Stoter G, et al. Clinical pharmacokinetics and metabolism of irinotecan (CPT-11). Clin Cancer Res : an official journal of the American Association for Cancer Research. 2001;7(8):2182–94.
Cited by
25 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献